Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, Arizona; Department of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
J Pain. 2022 Nov;23(11):1799-1810. doi: 10.1016/j.jpain.2022.06.009. Epub 2022 Jul 8.
Despite a rapid expansion of cannabis use for pain management, how cannabis and prescription opioids are co-used and whether co-use improves analgesia and promotes reduction of opioid use in the daily lives of individuals with chronic pain is poorly understood. Based upon ecological momentary assessment (EMA), the present study examined 1) how pain and use of opioids and/or cannabis in the previous moment is associated with individuals' choice of opioids and/or cannabis in the next moment, 2) the effects of co-use on pain severity and pain relief, and 3) whether daily total opioid consumption differs on days when people only used opioids versus co-used. Adults with chronic pain (N = 46) using both opioids and cannabis who were recruited online completed a 30-day EMA. Elevated pain did not increase the likelihood of co-use in subsequent momentary assessments. Switching from sole use of either opioids and cannabis to co-use was common. Neither co-use nor sole use of either cannabis or opioids were associated with reductions in pain in the next moment. However, participants reported the highest daily perceived pain relief from co-use compared to cannabis and opioid use only. Post hoc analysis suggested recall bias as a potential source of this discrepant findings between momentary versus retrospective assessment. Lastly, there was no evidence of an opioid-sparing effect of cannabis in this sample. The present study shows preliminary evidence on cannabis and opioid co-use patterns, as well as the effects of co-use on pain and opoid dose in the real-world setting. PERSPECTIVE: This article presents the overall patterns and effects of co-using cannabis and prescription opioids among individuals with chronic pain employing ecological momentary assessment. There were conflicting findings on the association between co-use and analgesia. Co-use was not associated with a reduction in daily opioid consumption in this sample.
尽管大麻在疼痛管理中的使用迅速扩大,但人们对大麻和处方类阿片类药物的共同使用方式、共同使用是否能改善镇痛效果以及促进慢性疼痛患者减少阿片类药物的使用知之甚少。基于生态瞬时评估(EMA),本研究考察了:1)前一刻的疼痛和阿片类药物和/或大麻的使用情况如何与个体在下一刻选择阿片类药物和/或大麻相关联;2)共同使用对疼痛严重程度和疼痛缓解的影响;3)在仅使用阿片类药物和共同使用的日子里,每天的总阿片类药物消耗量是否存在差异。在线招募的慢性疼痛成年人(N=46)同时使用阿片类药物和大麻,完成了 30 天的 EMA。下一刻评估中,疼痛加重并没有增加共同使用的可能性。从单独使用阿片类药物和大麻转为共同使用的情况很常见。无论是共同使用还是单独使用大麻或阿片类药物,都与下一刻的疼痛缓解无关。然而,与单独使用大麻或阿片类药物相比,参与者报告共同使用时的每日感知疼痛缓解程度最高。事后分析表明,回忆偏倚可能是造成这种即时评估与回顾性评估结果不一致的潜在原因。最后,在该样本中没有发现大麻有节省阿片类药物的作用。本研究初步证明了在真实环境中,大麻和处方类阿片类药物共同使用的模式,以及共同使用对疼痛和阿片类药物剂量的影响。观点:本文介绍了慢性疼痛患者共同使用大麻和处方类阿片类药物的总体模式和影响,以及共同使用对疼痛和阿片类药物剂量的影响。在共同使用与镇痛之间的关联上存在相互矛盾的结果。在该样本中,共同使用与每日阿片类药物消耗量的减少无关。